Syeda Ijlal Zehra Zaidi, Tanvir Ali Khan Shirwany


Background: Adipokines have been implicated in the modulation of insulin sensitivity and glucose tolerance and have thus gained importance in the study of Type 2 diabetes mellitus (T2DM). Resistin, a unique signalling molecule, is being proposed as a significant factor in the pathogenesis of obesity-related insulin resistance. However, its relevance to human diabetes mellitus remains uncertain and controversial. This study was therefore planned to compare and correlate the potential role of resistin in obese patients with T2DM and obese non-diabetic controls and also to evaluate the correlation between resistin and marker of obesity and glycaemic parameters. Methods: Fasting serum resistin, glucose and insulin were measured in forty obese diabetics (mean±SD BMI 35±5 kg/m2) and forty obese non-diabetics (mean±SD BMI 33±3 kg/m2). Insulin resistance was assessed using the HOMA-IR formula derived from fasting insulin and glucose levels. Results: Serum resistin levels (38±8 ng/ml) were significantly higher in type 2 diabetic patients as compared with the controls. Fasting blood glucose (164±46 mg/dl), serum insulin (37±7 µU/ml) and insulin resistance (19±8), were considerably higher among the studied diabetics than in the controls. Pearson’s correlation analysis revealed positive correlation between serum resistin and BMI (p=0.001) and HOMA-IR (p=0.561) in diabetic subjects. Similarly, a correlation also existed between serum resistin and BMI (p=0.016) and HOMA-IR (p=0.307) in control obese subjects. However, it was highly significant in diabetics as compared to non-diabetic controls. Conclusion: A significant BMI-dependent association exists between resistin and insulin resistance in patients with T2DM. It appears that resistin may play a role in the pathogenesis of obesity and insulin resistance and that both of these may contribute to the development of T2DM.

Full Text:



WHO. Diabetes Facts. [Internet]. [Cited 2012 Aug 21] Available at: URL;http://who.intdietphysicalactivity/publications/facts/diabetes/en

Shaw JE, Sicree RA , Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87(1):4–14.

Obesity — Global Issues [Internet]. [Cited 2012 Aug 21]. Available from:

WHO. Obesity and overweight [Internet]. [Cited 2012 Aug 21]. Available from:

Qatanani M, Szwergold NR, Greaves DR, Ahima R, Lazar MA. Macrophage- derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J Clin Invest 2009;119(3):531–9.

Qatanani M, Lazar MA. Mechanism of obesity–associated insulin resistance: many choices on the menu. Genes Dev 2007;21(12):1443–5.

Zhang H, Zhang C. Regulation of microvascular functions by adipose tissue in obesity and type2 diabetes. Evidence of an adipose-vascular loop. Am J Biomed Sci 2009;1(2):133–42.

Rabe K, lehrke M, Parhofer KG, Broedl U. Adipokines and insulin resistance. Mol Med 2008;14(11-12):741–51.

Unger RH, Grundy S. Hyperglycemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia 1985;28(3):119–21.

Steppan CM, Bailey ST, Bhat S, Brown EJ. Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature 2001;409(6818):307–12.

Barnes KM, Miner JL. Role of resistin in insulin sensitivity in rodents and humans. Curr Protein Pept Sci 2009;10(1):96–107.

Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K, Hilton DJ, et al. SOCS-3inhibits insulin signaling and is upregulated in respose to tumor necrosis factor α in the adipose tissue of obese mice. J Biol Chem 2001;276(51):47944–9.

Chanchay S, Tungtrongchitr R, Hamroongroj T, Phonrat B, Rungseesakorn O, Paksanont S, et al. Plasma resistin, insulin concentration in non diabetic and diabetic, overweight/ obese Thai. Int J Vitam Nutr Res 2006;76(3):125–31.

Gharibeh MY, Al Tawallbeh GM, Abboud MM, Radaideh A, Alhader AA, Khabour OF. Correlation of plasma resistin with obesity and insulin resistance in type 2 diabetic patients. Diabetes Metab 2010;36:443–9.

Mohammad zadeh G, Zarghami N, Mobaseri M. Serum resistin concentration in obese diabetic patients: Any possible relation to insulin resistin indices? Int J Endocrinol Metab 2008;6(4):183–93.

Sinorita H, Asdie RH, Pramono RB, Purnama LB, Asdie AH. Leptin, Adiponectin and Resistin Concentration in Obesity Class 1 and 2 at Sardjito Hospital Yogyakarta. Acta Med Indones 2010;42(2):74–7.

Asano H, Izawa H, Nagata K, Nakatochi M, Kobayashi M, Hirashiki A, et al. Plasma resistin concentration determined by common variants in the resistin gene and associated with metabolic traits in an aged Japanese population. Diabetologia 2010;53(2):795–7.

Al-Harithy RN, Al- Ghamdi S. Serum resistin, adipocity and insulin resistin in Saudi women with type 2 diabetes mellitus. Ann Saudi Med 2005; 25(4):283–7.

Rajala MW, Qi Y, Patel HR, Takahashi N, Banerjee R, Pajvani UB, et al. Regulation of Resistin expression and circulating levels in obesity , diabetes and fasting. Diabetes 2004;53(7):1671–9.

Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008;34(1):2–11.

American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2011;34:62–9.


  • There are currently no refbacks.

Contact Number: +92-992-382571

email: [jamc] [@] []